Meet the 2026 Class of RAPS Fellows

Three regulatory affairs professionals have been recognized as the 2026 RAPS Fellows.

Each year, our society honors a new class of RAPS Fellows for their noteworthy and sustained leadership contributions to their organizations, to RAPS, and to the regulatory affairs profession. 

RAPS Fellows hold the FRAPS designation and serve as important advisors and mentors for strategic collaboration, implementation of special initiatives, and international development across the regulatory community. Each new Fellow will be honored at RAPS Convergence 2026 on 15-17 September in Charlotte, North Carolina.

Shekhar Natarajan is an experienced biotechnology leader with nearly three decades of industry experience across regulatory affairs and policy. He currently serves as vice president, international regulatory affairs and policy at Dyne Therapeutics, a biotechnology company developing therapies for people living with genetically driven neuromuscular diseases. A recognized leader in rare disease drug development, Shekhar is a strong advocate for addressing unmet medical needs in this field. He serves as chair of the Therapies Scientific Committee of the International Rare Diseases Research Consortium (IRDiRC) and is active in European regulatory and policy initiatives through EU trade association EUCOPE and other regulatory bodies as an expert industry representative.

Ola Oyinloye, RAC-Devices, is a global regulatory affairs leader and advocate for advancing the regulatory profession with expertise spanning medical devices, combination products, digital health technologies, and global regulatory strategy. She is the regulatory science director at Novo Nordisk, where she integrates scientific and regulatory intelligence to inform enterprise decision-making. Her work anticipates competitive pathways, approval timelines, and emerging regulatory, quality and clinical trends, translating insights into strategic actions that strengthen pipeline development, accelerate innovation, and enhance long-term business competitiveness. She is an active contributor to EFPIA and BioPhorum, chair of the RAPS UK Local Networking Group, and is a member of both the RAC-Devices Committee and the RAPS Regulatory Intelligence Europe Conference Planning Committee.

Mike Ryan is an experienced regulatory leader who played a central role in modernizing regulatory processes as a regulatory advisor and senior leader at the US Food and Drug Administration (FDA). Over 21 years at FDA, he worked across the full spectrum of premarket review, postmarket surveillance, and policy development in the Center for Devices and Radiological Health. During his tenure at FDA, Mike served as a lead premarket reviewer and a total product life cycle manager, where he reviewed and oversaw hundreds of premarket submissions, developed dozens of regulations and guidance documents, and lead continuous improvement and transformative initiatives in compliance and postmarket surveillance. He is now executive vice president, medical devices and combination products at Eliquent. 

RAPS Fellows are selected based on eligibility criteria after application and review by the RAPS Fellows Committee. Learn more about the RAPS Fellows here.